Rise in the number of patients suffering from HIV infection is the factor basically augmenting the HIV drugs market. Notable R&D, promotion of awareness programs run by the government and non-government agencies, and new product launches are keeping the momentum going for the antiretroviral drugs landscape.
The companies operating in the HIV drugs market are collaborating with the governments of countries in Middle East & Africa, Latin America, and Asia Pacific to create an awareness regarding the importance of timely detection of HIV, so as to avoid reaching the stage where AIDS is incurable.
They are also exploring the opportunities to distribute generic versions of HIV drugs at subsidized rates in these regions.
Acquired Immuno Deficiency Virus (AIDS) is amongst the most dangerous and chronic diseases caused by Human Immuno Deficiency Virus (HIV). It is referred to as a viral infection that gets transmitted through exposure to HIV-infected blood, semen, and the other infected agents.
Rise in patient population along with novel product launches are expected to fuel the HIV drugs market.
The key players are engaged in various investment initiatives to increase their market share as well as create awareness about the dreadfulness of HIV infection. In August 2023, Aurobindo Pharma announced plans of introducing HIV drug for children stay put in 123 countries. The company as a pediatric dolutegravir voluntary license along with ViiV Healthcare.
However, lack of even distribution of HIV drugs is hampering the HIV drugs market. This is due to the lack of awareness regarding the initial signs of HIV infection. For instance, as per a study conducted by BioMed Central Ltd. in Europe, 33% of 467 participants living with HIV were unaware of their symptoms pertaining to HIV in 2017.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the WHO, 33 million individuals across the globe are HIV-positive and close to 1.7 million new cases are recorded every year. It further states that the year 2022 alone witnessed 22 fatalities by HIV infection. Moreover, as per the United Nations Programme on HIV/AIDS (UNAIDS), North America witnessed 2.2 million HIV-positive patients in 2019.
The huge patient population as mentioned above is generating an intense demand for antiretroviral (ARV) drugs. Moreover, the governments all over are taking steps for improving access to diagnosis as well as treatment of the HIV patients. This factor is anticipated to catalyze the HIV drugs market during the forecast period.
As per the International AIDS Society (IAS), integrase inhibitors are recommended as an initial treatment for HIV infection. However, new drugs are superseding this course of treatment.
Companies such as Gilead Sciences, ViiV Healthcare, Merck, and Janssen Pharmaceuticals, Inc. constitute a major portion of HIV drugs market. The dominance comes out of strong sales of the antiretroviral drugs with strategic collaborations and new product launches for enlarging the product portfolios.
In March 2021, Gilead Sciences Inc. collaborated with Merck Sharp & Dohme to co-develop and co-commercialize long-acting treatment with combinations of Lenacapavir and Islatravir for the HIV patients.
The ongoing trend is that of creation of antiretroviral treatment as a long-acting suppression (ATLAS) along with the first long-acting injectable formulation.
The new ATLAS regimens comprise combining rilpivirine and cabotegravir, which can be used as an alternative to the HIV medications that are already available. This therapy cuts down the days of dosage to 12 from 365 per year.
Continual focus on research related to HIV drugs is thus expanding the HIV drugs market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest HIV drugs market analysis, North America held the largest share in the HIV medications landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to rise in the incidence of HIV infections. As per a study conducted by the CDC in 2021, around 1.2 million individuals are living with HIV in the U.S.
Europe’s significant HIV drugs market share is ascribed to rise in the number of strategic collaborations amongst the companies to increase the frequency of drug availability. For instance, in July 2020, Theratechnologies Europe Limited entered into collaboration with Loxxess to distribute Trogarzo, one of the antiretroviral drugs all across the Europe.
The key players in the HIV drugs market are involving themselves in new products launch followed by approvals from regulatory authorities to establish a strong foothold. For instance, in February 2022, ViiV Healthcare received approval from the U.S. FDA for its Cabenuva (cabotegravir, rilpivirine) for treating individuals suffering from HIV infection.
Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GSK plc, AbbVie Inc., Cipla Limited, Bristol-Myers Squibb Company, and Merck & Co., Inc. are some of the key players covered in the HIV drugs industry report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 28.6 Bn |
| Market Forecast (Value) in 2034 | US$ 47.5 Bn |
| Growth Rate (CAGR) | 4.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 28.6 Bn in 2023
It is projected to grow at a CAGR of 4.7% from 2024 to 2034
Growing prevalence of HIV infections and rise in focus on R&D pertaining to HIV drugs
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GSK plc, AbbVie Inc., Cipla Limited, Bristol-Myers Squibb Company, and Merck & Co., Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global HIV Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global HIV Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global HIV Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
6.3.3. Protease Inhibitors (PIs)
6.3.4. Fusion Inhibitors (FIs)
6.3.5. C-C Chemokine Receptor Type 5 (CCR5)
6.3.6. Integrase Inhibitors
6.3.7. Attachment Inhibitors
6.3.8. Post Attachment Inhibitors
6.3.9. Pharmacokinetic Enhancers
6.3.10. Post-Exposure Prophylaxis (PEP)
6.3.11. Pre-Exposure Prophylaxis (PrEP)
6.3.12. Others (Combination HIV Medications, etc.)
6.4. Market Attractiveness Analysis, by Drug Type
7. Global HIV Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2020-2034
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global HIV Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America HIV Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Type, 2020-2034
9.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
9.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
9.3.3. Protease Inhibitors (PIs)
9.3.4. Fusion Inhibitors (FIs)
9.3.5. C-C Chemokine Receptor Type 5 (CCR5)
9.3.6. Integrase Inhibitors
9.3.7. Attachment Inhibitors
9.3.8. Post Attachment Inhibitors
9.3.9. Pharmacokinetic Enhancers
9.3.10. Post-Exposure Prophylaxis (PEP)
9.3.11. Pre-Exposure Prophylaxis (PrEP)
9.3.12. Others (Combination HIV Medications, etc.)
9.4. Market Value Forecast, by Distribution Channel, 2020-2034
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Type
9.6.2. By Distribution Channel
9.6.3. By Country
10. Europe HIV Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2020-2034
10.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
10.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.3.3. Protease Inhibitors (PIs)
10.3.4. Fusion Inhibitors (FIs)
10.3.5. C-C Chemokine Receptor Type 5 (CCR5)
10.3.6. Integrase Inhibitors
10.3.7. Attachment Inhibitors
10.3.8. Post Attachment Inhibitors
10.3.9. Pharmacokinetic Enhancers
10.3.10. Post-Exposure Prophylaxis (PEP)
10.3.11. Pre-Exposure Prophylaxis (PrEP)
10.3.12. Others (Combination HIV Medications, etc.)
10.4. Market Value Forecast, by Distribution Channel, 2020-2034
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Distribution Channel
10.6.3. By Country/Sub-region
11. Asia Pacific HIV Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2020-2034
11.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
11.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.3.3. Protease Inhibitors (PIs)
11.3.4. Fusion Inhibitors (FIs)
11.3.5. C-C Chemokine Receptor Type 5 (CCR5)
11.3.6. Integrase Inhibitors
11.3.7. Attachment Inhibitors
11.3.8. Post Attachment Inhibitors
11.3.9. Pharmacokinetic Enhancers
11.3.10. Post-Exposure Prophylaxis (PEP)
11.3.11. Pre-Exposure Prophylaxis (PrEP)
11.3.12. Others (Combination HIV Medications, etc.)
11.4. Market Value Forecast, by Distribution Channel, 2020-2034
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region
12. Latin America HIV Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2020-2034
12.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
12.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.3.3. Protease Inhibitors (PIs)
12.3.4. Fusion Inhibitors (FIs)
12.3.5. C-C Chemokine Receptor Type 5 (CCR5)
12.3.6. Integrase Inhibitors
12.3.7. Attachment Inhibitors
12.3.8. Post Attachment Inhibitors
12.3.9. Pharmacokinetic Enhancers
12.3.10. Post-Exposure Prophylaxis (PEP)
12.3.11. Pre-Exposure Prophylaxis (PrEP)
12.3.12. Others (Combination HIV Medications, etc.)
12.4. Market Value Forecast, by Distribution Channel, 2020-2034
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa HIV Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2020-2034
13.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
13.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.3.3. Protease Inhibitors (PIs)
13.3.4. Fusion Inhibitors (FIs)
13.3.5. C-C Chemokine Receptor Type 5 (CCR5)
13.3.6. Integrase Inhibitors
13.3.7. Attachment Inhibitors
13.3.8. Post Attachment Inhibitors
13.3.9. Pharmacokinetic Enhancers
13.3.10. Post-Exposure Prophylaxis (PEP)
13.3.11. Pre-Exposure Prophylaxis (PrEP)
13.3.12. Others (Combination HIV Medications, etc.)
13.4. Market Value Forecast, by Distribution Channel, 2020-2034
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Teva Pharmaceutical Industries Ltd.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Boehringer Ingelheim International GmbH
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Johnson & Johnson
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. F. Hoffmann-La Roche Ltd.
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Gilead Sciences, Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. GSK plc
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. AbbVie Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Cipla Limited
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Bristol-Myers Squibb Company
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Merck & Co., Inc.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 02: Global HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 03: Global HIV Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 04: North America HIV Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 05: North America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 06: North America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 07: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 09: Europe HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 10: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 12: Asia Pacific HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 13: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 15: Latin America HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 16: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
Table 18: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global HIV Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global HIV Drugs Market Revenue (US$ Bn), by Drug Type, 2023
Figure 03: Global HIV Drugs Market Value Share, by Drug Type, 2023
Figure 04: Global HIV Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 05: Global HIV Drugs Market Value Share, by Distribution Channel, 2023
Figure 06: Global HIV Drugs Market Value Share, by Region, 2023
Figure 07: Global HIV Drugs Market Value (US$ Bn) Forecast, 2020-2034
Figure 08: Global HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 09: Global HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 10: Global HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 11: Global HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Figure 12: Global HIV Drugs Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Global HIV Drugs Market Attractiveness Analysis, by Region, 2020-2034
Figure 14: North America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America HIV Drugs Market Attractiveness Analysis, by Country, 2020-2034
Figure 16: North America HIV Drugs Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 18: North America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 19: North America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 20: North America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Figure 21: Europe HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 23: Europe HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 25: Europe HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 26: Europe HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 27: Europe HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Figure 28: Asia Pacific HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 30: Asia Pacific HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 32: Asia Pacific HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 34: Asia Pacific HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Figure 35: Latin America HIV Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 37: Latin America HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 39: Latin America HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 40: Latin America HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 41: Latin America HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Figure 42: Middle East & Africa HIV Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2034
Figure 44: Middle East & Africa HIV Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa HIV Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
Figure 46: Middle East & Africa HIV Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 47: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Drug Type, 2020-2034
Figure 48: Middle East & Africa HIV Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
HIV Drugs Market
